600,000 shares and 2 cents up after the chief science officers leaves no room to misinterpret the findings of the data released this AM. The market could give one sh!t about Vascepa and this is directly due to the sentiment the FDA it's done jacking Amarin around.
Not fighting SPA is the worst managerial mistake ever and could cost this company a delisting if the FDA also rescinds RI. There's zero assurance the FDA won't pull the placebo trick out of the hat!
Market Data 
Markets 
AI
